Tarsus Pharmaceuticals, Inc.
TARS
$40.81
$1.995.13%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 78.34M | 66.41M | 48.12M | 40.81M | 27.61M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 78.34M | 66.41M | 48.12M | 40.81M | 27.61M |
| Cost of Revenue | 19.62M | 21.80M | 15.37M | 15.32M | 13.72M |
| Gross Profit | 58.72M | 44.61M | 32.75M | 25.49M | 13.89M |
| SG&A Expenses | 85.00M | 69.03M | 57.91M | 58.79M | 51.58M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 104.62M | 90.83M | 73.28M | 74.12M | 65.30M |
| Operating Income | -26.28M | -24.42M | -25.16M | -33.30M | -37.68M |
| Income Before Tax | -25.12M | -23.11M | -23.42M | -33.29M | -35.73M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -25.12M | -23.11M | -23.42M | -33.29M | -35.73M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.12M | -23.11M | -23.42M | -33.29M | -35.73M |
| EBIT | -26.28M | -24.42M | -25.16M | -33.30M | -37.68M |
| EBITDA | -25.82M | -23.99M | -24.88M | -33.06M | -37.41M |
| EPS Basic | -0.64 | -0.60 | -0.61 | -0.88 | -1.01 |
| Normalized Basic EPS | -0.42 | -0.33 | -0.38 | -0.52 | -0.64 |
| EPS Diluted | -0.64 | -0.60 | -0.61 | -0.88 | -1.01 |
| Normalized Diluted EPS | -0.42 | -0.33 | -0.38 | -0.52 | -0.64 |
| Average Basic Shares Outstanding | 39.35M | 38.56M | 38.38M | 37.82M | 35.30M |
| Average Diluted Shares Outstanding | 39.35M | 38.56M | 38.38M | 37.82M | 35.30M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |